<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="36196" end="36201" sStart="36129" offset="67" sid="r7.1.use.v.0688" wn="1" wnkey="use%2:34:01::" text="During the preparation of this manuscript, a similar study using a recombinant Ad-mIL-4 vector for treatment of murine CIA was reported [ 31]." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/ar104.anc" start="2429" end="2434" sStart="null" offset="0" sid="null" wn="1" wnkey="time%1:11:00::" text="The ability of Ad-mIL-4 to treat established CIA was evaluated by local periarticular and systemic intravenous injection of Ad-mIL-4 into mice at various &lt;b&gt;times&lt;/b&gt; after disease onset." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/ar104.anc" start="2429" end="2434" sStart="null" offset="0" sid="null" wn="8" wnkey="time%1:28:04::" text="The ability of Ad-mIL-4 to treat established CIA was evaluated by local periarticular and systemic intravenous injection of Ad-mIL-4 into mice at various &lt;b&gt;times&lt;/b&gt; after disease onset." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="3497" end="3503" sStart="null" offset="245" sid="r11.severe.j.0427" wn="1" wnkey="severe%5:00:00:intense:00" text="Disease severity was monitored every other day using an established macroscopic scoring system ranging from 0 to 4: 0, normal; 1, detectable arthritis with erythma; 2, significant swelling and redness; 3, severe swelling and redness from joint to digit; and 4, maximal swelling with ankylosis." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="15840" end="15846" sStart="null" offset="234" sid="r11.severe.j.0428" wn="1" wnkey="severe%5:00:00:intense:00" text="Disease severity was assessed every other day using an established macroscopic scoring system ranging from 0 to 4: 0, normal; 1, detectable arthritis with erythma; 2, significant swelling and redness; 3, severe swelling and redness from joint to digit; and 4, maximal swelling with ankylosis." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar104.anc" start="18565" end="18569" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" text="Thereafter, plates were washed, incubated with 100 ? l 2,2-azino-di-(-3-ethyl-benzthiazolinesulfonate) substrate (ABTS; Boeringer Mannheim, Indianapolis, IN, USA) at 1mg/ml and &lt;b&gt;read&lt;/b&gt; at 405nm." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar104.anc" start="28633" end="28637" sStart="null" offset="0" sid="null" wn="1" wnkey="part%1:24:00::" text="In contrast, it is possible that the therapeutic effects of IL-4 after local injection are conferred in &lt;b&gt;part&lt;/b&gt; by IL-10." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="6419" end="6424" sStart="null" offset="99" sid="r1.order.n.0008" wn="2147483647" wnkey="null" text="Gene therapy represents a novel approach for delivery of therapeutic agents to joints in order to treat the pathologies associated with RA and osteoarthritis, as well as other disorders of the joints." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="6419" end="6424" sStart="null" offset="99" sid="r1.order.n.0008" wn="2147483647" wnkey="null" text="Gene therapy represents a novel approach for delivery of therapeutic agents to joints in order to treat the pathologies associated with RA and osteoarthritis, as well as other disorders of the joints." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="6419" end="6424" sStart="null" offset="99" sid="r1.order.n.0008" wn="2147483645" wnkey="null" text="Gene therapy represents a novel approach for delivery of therapeutic agents to joints in order to treat the pathologies associated with RA and osteoarthritis, as well as other disorders of the joints." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="6099" end="6105" sStart="null" offset="251" sid="r8.number.n.0777" wn="1" wnkey="number%1:07:00::" text="Whereas the immunized control mice, injected with Ad-eGFP, showed disease onset on day 3 after lipopolysaccharide injection, Ad-mIL-4-treated mice showed a delay in disease onset and as a reduction in the total number of arthritic paws." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="6926" end="6932" sStart="null" offset="179" sid="r8.number.n.0356" wn="1" wnkey="number%1:07:00::" text="We have demonstrated that both local and systemic administration of Ad-mIL-4 resulted in a reduction in the severity of arthritis, as well as in the number of arthritic paws." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="3391" end="3397" sStart="null" offset="139" sid="r9.normal.j.0769" wn="3" wnkey="normal%3:00:03::" text="Disease severity was monitored every other day using an established macroscopic scoring system ranging from 0 to 4: 0, normal; 1, detectable arthritis with erythma; 2, significant swelling and redness; 3, severe swelling and redness from joint to digit; and 4, maximal swelling with ankylosis." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="25650" end="25655" sStart="null" offset="80" sid="r9.level.n.0333" wn="1" wnkey="level%1:07:00::" text="In addition, expression of IL-4 resulted in a twofold increase in the level of endogenous IL-1Ra (data not shown)." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="24706" end="24712" sStart="null" offset="4" sid="r9.level.n.0471" wn="1" wnkey="level%1:07:00::" text="The levels of IL-4 and IL-10 expression also were examined in arthritic mice treated with Ad-mIL-4 at day 35 after injection." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="13987" end="13994" sStart="null" offset="88" sid="r10.control.n.0271" wn="2" wnkey="control%1:24:00::" text="The inserted cDNA sequences are expressed under the transcriptional control of human cytomegalovirus promoter." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="21159" end="21166" sStart="null" offset="35" sid="r10.control.n.0354" wn="1" wnkey="control%1:07:00::" text="2a) compared with the nonarthritic control joints." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="1371" end="1382" sStart="null" offset="247" sid="r11.combination.n.0758" wn="1" wnkey="combination%1:14:00::" text="IL-4, similar to tumor necrosis factor (TNF)-? and IL-1 inhibitors, has been shown be therapeutic for the treatment of murine CIA when administered intravenously as a recombinant protein, either alone or in combination with IL-10." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="10181" end="10192" sStart="null" offset="207" sid="r11.combination.n.0047" wn="1" wnkey="combination%1:14:00::" text="IL-4, similar to TNF-? and IL-1 inhibitors, has been shown be therapeutic for the treatment of murine CIA when administered intravenously as a recombinant protein, either alone or in combination with IL-10." />
    <s path="[OANC]/data/written_2/technical/biomed/ar104.anc" start="10181" end="10192" sStart="null" offset="207" sid="r11.combination.n.0047" wn="7" wnkey="combination%1:04:00::" text="IL-4, similar to TNF-? and IL-1 inhibitors, has been shown be therapeutic for the treatment of murine CIA when administered intravenously as a recombinant protein, either alone or in combination with IL-10." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/ar104.anc" start="16259" end="16265" sStart="null" offset="0" sid="null" wn="4" wnkey="add_together%2:31:00::" text="The paw swelling for each mouse was calculated by &lt;b&gt;adding&lt;/b&gt; the four thicknesses of the individual paws." />
  </sentences>
</list>